Rare-disease biotech selling Pyrukynd for pyruvate kinase deficiency, expanding into sickle cell and thalassemia.
Rare-disease biotech selling Pyrukynd for pyruvate kinase deficiency, expanding into sickle cell and thalassemia.
Since selling its cancer drugs to Servier in 2021, it has been a rare-blood-disease company, selling Pyrukynd in the US to a small number of patients. Value depends on whether the same drug wins approval in broader blood disorders.
Moat: narrow (IP / patents, regulatory licence). First-in-class pyruvate kinase activator with orphan-drug exclusivity in a rare-disease niche.
Headquarters: Cambridge, Massachusetts, US · Founded: 2007 · Employees: 540
Size Agios Pharmaceuticals (AGIO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.78B, the 1854th largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.68 on 18 Nov 2026.
Performance Over six months the shares gained 4.1%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 214.4% over the last twelve months (peer median +4.2%); the operating margin is -297.7% (peer median 10.0%).
Valuation It trades at 8.3× enterprise value to sales against a peer median of 3.6× (7th most expensive of 21).
Capital Return on invested capital runs 96.4 points below its cost of capital (8.3% WACC).
Short interest Short interest is 10.9% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $141M | $54.0M | $36.5M | $26.8M | $14.2M |
| Revenue growth | — | +48% | +36% | +88% | — |
| Gross profit | $127M | $42.5M | $26.7M | $17.3M | -$6.02M |
| EBITDA | -$414M | -$467M | -$420M | -$385M | -$370M |
| Net income | -$373M | -$413M | $674M | -$352M | -$232M |
| Free cash flow | -$336M | -$377M | -$392M | -$297M | -$314M |
| Capital expenditure | $4.28M | $4.32M | $1.69M | $999,000 | $4.88M |
| Total debt | $26.5M | $40.2M | $57.0M | $72.0M | $85.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals AGIO | $1.78B | +4% | +214% | -298% | 8.3× | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 3.9× | -0.5% |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 10.5× | 6.2% |
| Beam Therapeutics BEAM | $2.17B | -22% | +163% | -268% | 9.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AGIO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.0% | +0.5% | lowest of 21 |
| 6-month return | +4.1% | -4.7% | 7th highest of 21 |
| Distance from 52-week high | -35.5% | -32.1% | 9th lowest of 21 |
| Revenue growth (TTM) | +214.4% | +4.2% | highest of 21 |
| Operating margin | -297.7% | 10.0% | 2nd lowest of 21 |
| EV / Sales | 8.3× | 3.6× | 7th most expensive of 21 |
| ROIC minus cost of capital | -96.4 pp | +1.2 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | 8.3× | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 2.1× | -0.4% | -0.2% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 0.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 12.4× | 21.9% | +359.6% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 0.6× | 1.2% | +7.8% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 2.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 3.7× | n/a | n/a |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 8.9× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 0.3× | -9.5% | +4.2% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 1.9× | -6.0% | +7.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 5.1× | 20.5% | +19.0% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 4.2× | 5.4% | +29.1% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 9.7× | 35.3% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | 68.8× | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 2.6× | 3.7% | +9.9% |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 2.3× | -3.4% | +8.0% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 16.7× | 11.3% | -11.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | 25.8× | n/a | n/a |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 6.3× | 24.3% | +15.7% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 2.3× | -3.5% | +6.8% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 3.6× | 31.4% | +29.4% |